Modern Biosciences has entered into an R&D alliance and global option and licence agreement with Janssen Biotech in relation to MBS’ novel bone-protective compounds for the treatment of rheumatoid arthritis.
The goal of the collaboration, facilitated by the Johnson & Johnson Innovation Centre in London, is to develop new drugs for the treatment of RA.
Under the terms of the exclusive agreement, Modern Biosciences will receive an up-front payment and is eligible to receive development, regulatory and commercialisation milestone payments up to a potential total of £176 million.
In addition, MBS will receive royalties on future sales of any products that may result from the alliance upon successful launch and commercialisation.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends